Ivanyi P - Search Results

1

Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients.

Stöhr CG, Steffens S, Polifka I, Jung R, Kahlmeyer A, Ivanyi P, Weber F, Hartmann A, Wullich B, Wach S, Taubert H. Stöhr CG, et al. Among authors: ivanyi p. Sci Rep. 2019 Feb 11;9(1):1741. doi: 10.1038/s41598-018-38254-3. Sci Rep. 2019. PMID: 30741998 Free PMC article.

2

Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients.

Ivanyi P, Winkler T, Grosshennig A, Reuter C, Merseburger AS, Ganser A, Grünwald V. Ivanyi P, et al. World J Urol. 2010 Jun;28(3):311-7. doi: 10.1007/s00345-010-0558-y. Epub 2010 May 5. World J Urol. 2010. PMID: 20443009

3

Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?

Ivanyi P, Koenig J, Trummer A, Busch JF, Seidel C, Reuter CW, Ganser A, Grünwald V. Ivanyi P, et al. World J Urol. 2016 Jul;34(7):909-15. doi: 10.1007/s00345-015-1707-0. Epub 2015 Nov 19. World J Urol. 2016. PMID: 26586475

4

Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?

Abbas M, Steffens S, Bellut M, Becker JU, Großhennig A, Eggers H, Wegener G, Kuczyk MA, Kreipe HH, Grünwald V, Schrader AJ, Ivanyi P. Abbas M, et al. Among authors: ivanyi p. Med Oncol. 2016 Jun;33(6):59. doi: 10.1007/s12032-016-0770-8. Epub 2016 May 10. Med Oncol. 2016. PMID: 27165272

5

Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).

Abbas M, Steffens S, Bellut M, Eggers H, Großhennig A, Becker JU, Wegener G, Schrader AJ, Grünwald V, Ivanyi P. Abbas M, et al. Among authors: ivanyi p. Med Oncol. 2016 Jul;33(7):80. doi: 10.1007/s12032-016-0794-0. Epub 2016 Jun 17. Med Oncol. 2016. PMID: 27317388

6

PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?

Erlmeier F, Hartmann A, Autenrieth M, Wiedemann M, Ivanyi P, Steffens S, Weichert W. Erlmeier F, et al. Among authors: ivanyi p. Med Oncol. 2016 Nov;33(11):120. doi: 10.1007/s12032-016-0833-x. Epub 2016 Sep 30. Med Oncol. 2016. PMID: 27696122

7

[c-MET Oncogene in Renal Cell Carcinomas].

Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S. Erlmeier F, et al. Among authors: ivanyi p. Aktuelle Urol. 2016 Dec;47(6):475-479. doi: 10.1055/s-0042-115401. Epub 2016 Dec 22. Aktuelle Urol. 2016. PMID: 28006830 Review. German.

8

c-Met in chromophobe renal cell carcinoma.

Erlmeier F, Ivanyi P, Hartmann A, Autenrieth M, Wiedemann M, Weichert W, Steffens S. Erlmeier F, et al. Among authors: ivanyi p. Med Oncol. 2017 Feb;34(2):15. doi: 10.1007/s12032-016-0874-1. Epub 2016 Dec 29. Med Oncol. 2017. PMID: 28035577

9

PD-L2: A prognostic marker in chromophobe renal cell carcinoma?

Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, Ivanyi P, Steffens S. Erlmeier F, et al. Among authors: ivanyi p. Med Oncol. 2017 May;34(5):71. doi: 10.1007/s12032-017-0926-1. Epub 2017 Mar 28. Med Oncol. 2017. PMID: 28353093

10

Prognostic impact of PD-1 and its ligands in renal cell carcinoma.

Erlmeier F, Weichert W, Schrader AJ, Autenrieth M, Hartmann A, Steffens S, Ivanyi P. Erlmeier F, et al. Among authors: ivanyi p. Med Oncol. 2017 Jun;34(6):99. doi: 10.1007/s12032-017-0961-y. Epub 2017 Apr 21. Med Oncol. 2017. PMID: 28432616 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page